Valneva SE
VALN
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$6.96
Price+2.05%
$0.14
1Y
Price
Market Cap
$659.970m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in EUR.-63.0%
EBITDA Margin-103.8%
Net Profit Margin-1.8%
Free Cash Flow Margin-63.0%
EBITDA Margin-103.8%
Net Profit Margin-1.8%
Free Cash Flow MarginRevenue
$156.329m
-10.5%
1y CAGR+0.9%
3y CAGR-13.7%
5y CAGREarnings
-$138.033m
-19.8%
1y CAGR-257.5%
3y CAGR-185.8%
5y CAGREPS
-$1.63
-23.5%
1y CAGR-203.9%
3y CAGR-142.6%
5y CAGRBook Value
$76.779m
$372.401m
Assets$295.314m
Liabilities$209.723m
DebtDebt to Assets
56.3%
-2.7x
Debt to EBITDAFree Cash Flow
-$70.918m
-23.6%
1y CAGR+23.1%
3y CAGR+22.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company